{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:00:42Z","timestamp":1781503242733,"version":"3.54.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10523-1","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T09:17:22Z","timestamp":1745227042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of signaling pathways in endometrial cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8407-242X","authenticated-orcid":false,"given":"Nikita","family":"Balhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-2369","authenticated-orcid":false,"given":"Ritu","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi B.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"10523_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. Cancer J Clin, 72(1)","DOI":"10.3322\/caac.21708"},{"issue":"4","key":"10523_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1257\/jep.35.4.123","volume":"35","author":"BK Couillard","year":"2021","unstructured":"Couillard BK, Foote CL, Gandhi K, Meara E, Skinner J (2021) Rising geographic disparities in US mortality. J Economic Perspect 35(4):123\u2013146","journal-title":"J Economic Perspect"},{"key":"10523_CR3","doi-asserted-by":"crossref","unstructured":"Abdelmaksoud NM, El-Mahdy HA, Ismail A, Elsakka EG, El-Husseiny AA, Khidr EG, Doghish AS (2023) The role of MiRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: a spotlight on the convergence of signaling pathways. Pathology-Research Pract, 154411","DOI":"10.1016\/j.prp.2023.154411"},{"issue":"2","key":"10523_CR4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s11033-019-05226-3","volume":"47","author":"K Skok","year":"2020","unstructured":"Skok K, Maver U, Gradi\u0161nik L, Kozar N, Taka\u010d I, Arko D (2020) Endometrial cancer and its cell lines. Mol Biol Rep 47(2):1399\u20131411","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10523_CR5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Mutch D (2023) FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet 162(2):383\u2013394","journal-title":"Int J Gynecol Obstet"},{"key":"10523_CR6","doi-asserted-by":"crossref","unstructured":"Passarello K, Kurian S, Villanueva V (2019, April) Endometrial cancer: an overview of pathophysiology, management, and care. Seminars in oncology nursing, vol 35. WB Saunders, pp 157\u2013165. 2","DOI":"10.1016\/j.soncn.2019.02.002"},{"issue":"3","key":"10523_CR7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2018.05.015","volume":"150","author":"RC Arend","year":"2018","unstructured":"Arend RC, Jones BA, Martinez A, Goodfellow P (2018) Endometrial cancer: molecular markers and management of advanced stage disease. Gynecol Oncol 150(3):569\u2013580","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10523_CR8","doi-asserted-by":"crossref","first-page":"e2332296","DOI":"10.1001\/jamanetworkopen.2023.32296","volume":"6","author":"R Katagiri","year":"2023","unstructured":"Katagiri R, Iwasaki M, Abe SK, Islam MR, Rahman MS, Saito E, Kang D (2023) Reproductive factors and endometrial cancer risk among women. JAMA Netw Open 6(9):e2332296\u2013e2332296","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10523_CR9","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/ijc.32514","volume":"145","author":"L Costas","year":"2019","unstructured":"Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pav\u00f3n M\u00c1, Screenwide Team (2019) New perspectives on screening and early detection of endometrial cancer. Int J Cancer 145(12):3194\u20133206","journal-title":"Int J Cancer"},{"issue":"1","key":"10523_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-023-01757-3","volume":"22","author":"Y Shen","year":"2023","unstructured":"Shen Y, Yang W, Liu J, Zhang Y (2023) Minimally invasive approaches for the early detection of endometrial cancer. Mol Cancer 22(1):53","journal-title":"Mol Cancer"},{"issue":"11","key":"10523_CR11","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/medicina60111866","volume":"60","author":"G Kaspute","year":"2024","unstructured":"Kaspute G, Bareikiene E, Prentice U, Uzieliene I, Ramasauskaite D, Ivaskiene T (2024) A comprehensive review of advanced diagnostic techniques for endometriosis: new approaches to improving women\u2019s Well-Being. Medicina 60(11):1866","journal-title":"Medicina"},{"issue":"16","key":"10523_CR12","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.3390\/cancers15164101","volume":"15","author":"W Zheng","year":"2023","unstructured":"Zheng W (2023) Molecular classification of endometrial cancer and the 2023 FIGO staging: exploring the challenges and opportunities for pathologists. Cancers 15(16):4101","journal-title":"Cancers"},{"issue":"2","key":"10523_CR13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/ijms25021056","volume":"25","author":"F Addante","year":"2024","unstructured":"Addante F, d\u2019Amati A, Santoro A, Angelico G, Inzani F, Arciuolo D, Zannoni GF (2024) Mismatch repair deficiency as a predictive and prognostic biomarker in endometrial cancer: a review on immunohistochemistry staining patterns and clinical implications. Int J Mol Sci 25(2):1056","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10523_CR14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s10038-021-00940-y","volume":"66","author":"S Mori","year":"2021","unstructured":"Mori S, Gotoh O, Kiyotani K, Low SK (2021) Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. J Hum Genet 66(9):853\u2013868","journal-title":"J Hum Genet"},{"key":"10523_CR15","first-page":"1","volume-title":"Gynecologic and obstetric pathology","author":"W Zheng","year":"2024","unstructured":"Zheng W, Fadare O, Quick CM (2024) Endometrial carcinogenesis. Gynecologic and obstetric pathology. Springer Nature Singapore.), Singapore, pp 1\u201324"},{"key":"10523_CR16","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","volume":"38","author":"R Murali","year":"2019","unstructured":"Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Soslow RA (2019) High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 38:S40\u2013S63","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10523_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/life14030387","volume":"14","author":"O Saglam","year":"2024","unstructured":"Saglam O (2024) Uncommon morphologic types of endometrial Cancer and their mimickers: how much does molecular classification improve the practice for challenging cases?? Life 14(3):387","journal-title":"Life"},{"key":"10523_CR18","doi-asserted-by":"crossref","unstructured":"Palacios J, Dal Cin P (2018) Molecular pathology and cytogenetics of endometrial carcinoma, carcinosarcoma, and uterine sarcomas. Uterine Cancer: Screen Diagnosis Treat, 85\u2013103","DOI":"10.1007\/7631_2015_6"},{"key":"10523_CR19","unstructured":"Jones ER (2023) Developing Tests for Endometrial Cancer Detection (DETECT) (Doctoral dissertation, The University of Manchester (United Kingdom))"},{"issue":"20","key":"10523_CR20","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.3390\/cancers14205020","volume":"14","author":"SK Chambers","year":"2022","unstructured":"Chambers SK (2022) Advances in chemotherapy and targeted therapies in endometrial cancer. Cancers 14(20):5020","journal-title":"Cancers"},{"issue":"94","key":"10523_CR21","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.18632\/oncotarget.26413","volume":"9","author":"S Lopez","year":"2018","unstructured":"Lopez S, Zeybek B, Santin AD (2018) Targeting Her2\/neu in uterine serous carcinoma: A paradigm shift in management. Oncotarget 9(94):36652","journal-title":"Oncotarget"},{"issue":"1","key":"10523_CR22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PGP.0000000000000585","volume":"39","author":"TT Yen","year":"2020","unstructured":"Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S (2020) Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol 39(1):26\u201335","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10523_CR23","first-page":"8199306","volume":"2022","author":"N Lachej","year":"2022","unstructured":"Lachej N, Dabkeviciene D, Simiene J, Sabaliauskaite R, Jonusiene V, Brasiunas V, Didziapetriene J (2022) Components of NOTCH signaling for uterine Cancer patients\u2019 prognosis. J Oncol 2022(1):8199306","journal-title":"J Oncol"},{"issue":"6","key":"10523_CR24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.30537","volume":"140","author":"NL Jones","year":"2017","unstructured":"Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, Hou JY (2017) Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer 140(6):1396\u20131404","journal-title":"Int J Cancer"},{"issue":"10","key":"10523_CR25","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3390\/cancers13102351","volume":"13","author":"I Fatima","year":"2021","unstructured":"Fatima I, Barman S, Rai R, Thiel KW, Chandra V (2021) Targeting Wnt signaling in endometrial cancer. Cancers 13(10):2351","journal-title":"Cancers"},{"issue":"3","key":"10523_CR26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/ijms23031237","volume":"23","author":"D Boro\u0144","year":"2022","unstructured":"Boro\u0144 D, Zmarz\u0142y N, Wierzbik-Stro\u0144ska M, Rosi\u0144czuk J, Mieszcza\u0144ski P, Grabarek BO (2022) Recent multiomics approaches in endometrial cancer. Int J Mol Sci 23(3):1237","journal-title":"Int J Mol Sci"},{"key":"10523_CR27","unstructured":"Han GH, Lu KJ, Wang P, Ye J, Ye YY, Huang JX (2018) LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt\/\u03b2-catenin signaling pathway. Eur Rev Med Pharmacol Sci, 22(12).)"},{"issue":"12","key":"10523_CR28","doi-asserted-by":"crossref","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane J, Gomis RR (2017) TGF-\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harb Perspect Biol 9(12):a022277","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10523_CR29","doi-asserted-by":"crossref","first-page":"111846","DOI":"10.1016\/j.intimp.2024.111846","volume":"131","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Z, Li S, Ma J, Dai X, Lu J (2024) Deciphering JAK\/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions. Int Immunopharmacol 131:111846","journal-title":"Int Immunopharmacol"},{"key":"10523_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","volume":"10","author":"AC Rodriguez","year":"2019","unstructured":"Rodriguez AC, Blanchard Z, Maurer KA, Gertz J (2019) Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm Cancer 10:51\u201363","journal-title":"Horm Cancer"},{"key":"10523_CR31","doi-asserted-by":"crossref","unstructured":"Liu X, Wang J, Zhou J (2024) The role of oestrogen and oestrogen-calcium axis in endometrial carcinoma. Gynecol Obstet Clin Med, 4(1)","DOI":"10.1136\/gocm-2024-000012"},{"key":"10523_CR32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.biopha.2018.04.020","volume":"103","author":"ZB Cincin","year":"2018","unstructured":"Cincin ZB, Kiran B, Baran Y, Cakmakoglu B (2018) Hesperidin promotes programmed cell death by downregulation of nongenomic Estrogen receptor signalling pathway in endometrial cancer cells. Biomed Pharmacother 103:336\u2013345","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10523_CR33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/biom11111739","volume":"11","author":"J Ke","year":"2021","unstructured":"Ke J, Ye J, Li M, Zhu Z (2021) The role of matrix metalloproteinases in endometriosis: A potential target. Biomolecules 11(11):1739","journal-title":"Biomolecules"},{"key":"10523_CR34","doi-asserted-by":"crossref","unstructured":"Jonusiene V, Sasnauskiene A (2021) Notch and endometrial cancer. Notch Signal Embryol Cancer: Notch Signal Cancer, 47\u201357","DOI":"10.1007\/978-3-030-55031-8_4"},{"issue":"1","key":"10523_CR35","first-page":"3","volume":"22","author":"WK You","year":"2023","unstructured":"You WK, Schuetz TJ, Lee SH (2023) Targeting the DLL\/Notch signaling pathway in cancer: challenges and advances in clinical development. Mol Cancer Ther 22(1):3\u201311","journal-title":"Mol Cancer Ther"},{"key":"10523_CR36","doi-asserted-by":"crossref","first-page":"786728","DOI":"10.3389\/fcell.2021.786728","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H (2021) TGF-\u03b2 signaling and resistance to cancer therapy. Front Cell Dev Biology 9:786728","journal-title":"Front Cell Dev Biology"},{"issue":"7","key":"10523_CR37","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/molecules28073043","volume":"28","author":"KK To","year":"2023","unstructured":"To KK, Xing E, Larue RC, Li PK (2023) BET bromodomain inhibitors: novel design strategies and therapeutic applications. Molecules 28(7):3043","journal-title":"Molecules"},{"issue":"1","key":"10523_CR38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev-biochem-040320-103615","volume":"91","author":"EY Rim","year":"2022","unstructured":"Rim EY, Clevers H, Nusse R (2022) The Wnt pathway: from signaling mechanisms to synthetic modulators. Annu Rev Biochem 91(1):571\u2013598","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"10523_CR39","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1021\/acs.jmedchem.0c01799","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang P, Wold EA, Song Q, Zhao C, Wang C, Zhou J (2021) Small-molecule inhibitors targeting the canonical WNT signaling pathway for the treatment of cancer. J Med Chem 64(8):4257\u20134288","journal-title":"J Med Chem"},{"key":"10523_CR40","doi-asserted-by":"crossref","first-page":"114789","DOI":"10.1016\/j.ejmech.2022.114789","volume":"243","author":"P Yang","year":"2022","unstructured":"Yang P, Zhu Y, Zheng Q, Meng S, Wu Y, Shuai W, Wang G (2022) Recent advances of \u03b2-catenin small molecule inhibitors for cancer therapy: current development and future perspectives. Eur J Med Chem 243:114789","journal-title":"Eur J Med Chem"},{"key":"10523_CR41","doi-asserted-by":"crossref","unstructured":"Zhao X, Ma Y, Luo J, Xu K, Tian P, Lu C, Song J (2024) Blocking the WNT\/\u03b2-catenin pathway in cancer treatment: Pharmacological targets and drug therapeutic potential. Heliyon, 10(16)","DOI":"10.1016\/j.heliyon.2024.e35989"},{"issue":"21","key":"10523_CR42","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"BM Slomovitz","year":"2012","unstructured":"Slomovitz BM, Coleman RL (2012) The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856\u20135864","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10523_CR43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W, Jones RH, Kumar AP (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138","journal-title":"Mol Cancer"},{"key":"10523_CR44","doi-asserted-by":"crossref","first-page":"1372376","DOI":"10.3389\/fonc.2024.1372376","volume":"14","author":"RC Pedrosa","year":"2024","unstructured":"Pedrosa RC, Felipe KB, Filho W, D (2024) Oncogenic PI3KT\/Akt\/mTOR pathway alterations, ROS homeostasis, targeted cancer therapy and drug resistance. Front Oncol 14:1372376","journal-title":"Front Oncol"},{"issue":"4","key":"10523_CR45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000530104","volume":"88","author":"C Zhong","year":"2023","unstructured":"Zhong C, Ju G, Yang S, Chen J, Li N (2023) Total flavonoids of polygala fallax Hemsl induce apoptosis of human ectopic endometrial stromal cells through PI3K\/AKT\/Bcl-2 signaling pathway. Gynecol Obstet Invest 88(4):197\u2013213","journal-title":"Gynecol Obstet Invest"},{"key":"10523_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-14-1","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang L, Wu J, Ling MT, Zhao L, Zhao KN (2015) The role of the PI3K\/Akt\/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer 14:1\u201313","journal-title":"Mol Cancer"},{"issue":"15","key":"10523_CR47","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/0008-5472.CAN-22-3032","volume":"83","author":"S Mafi","year":"2023","unstructured":"Mafi S, Ahmadi E, Meehan E, Chiari C, Mansoori B, Sadeghi H, Rostamzadeh D (2023) The mTOR signaling pathway interacts with the ER stress response and the unfolded protein response in cancer. Cancer Res 83(15):2450\u20132460","journal-title":"Cancer Res"},{"issue":"3","key":"10523_CR48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed A, Kim E, Jacinto E (2021) Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev 101(3):1371\u20131426","journal-title":"Physiol Rev"},{"key":"10523_CR49","doi-asserted-by":"crossref","unstructured":"Bostan IS, Mihaila M, Roman V, Radu N, Neagu MT, Bostan M, Mehedintu C (2024) Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy. Cancers, 16(11), 2027","DOI":"10.3390\/cancers16112027"},{"issue":"1","key":"10523_CR50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12929-023-00985-5","volume":"30","author":"J Mandal","year":"2023","unstructured":"Mandal J, Yu ZC, Shih IM, Wang TL (2023) ARID1A loss activates MAPK signaling via DUSP4 downregulation. J Biomed Sci 30(1):94","journal-title":"J Biomed Sci"},{"key":"10523_CR51","doi-asserted-by":"crossref","unstructured":"Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L.,\u2026 Berindan-Neagoe,I. (2019). A comprehensive review on MAPK: a promising therapeutic target in cancer.Cancers, 11(10), 1618.","DOI":"10.3390\/cancers11101618"},{"issue":"1","key":"10523_CR52","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/ijms23010370","volume":"23","author":"L Garc\u00eda-Hern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Hern\u00e1ndez L, Garc\u00eda-Ortega MB, Ruiz-Alcal\u00e1 G, Carrillo E, Marchal JA, Garc\u00eda M\u00c1 (2021) The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci 23(1):370","journal-title":"Int J Mol Sci"},{"key":"10523_CR53","doi-asserted-by":"crossref","unstructured":"Ali, E. S., Akter, S., Ramproshad, S., Mondal, B., Riaz, T. A., Islam, M. T.,\u2026 Cho,W. C. (2022). Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview. Cancer cell international, 22(1), 246.","DOI":"10.1186\/s12935-022-02666-z"},{"key":"10523_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","volume":"14","author":"K Chen","year":"2021","unstructured":"Chen K, Zhang Y, Qian L, Wang P (2021) Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol 14:1\u201323","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10523_CR55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Therapy 8(1):455","journal-title":"Signal Transduct Target Therapy"},{"key":"10523_CR56","unstructured":"Luo J (2011), May Targeting the Ras-MAPK Pathway for Cancer Therapy. In ANNALS OF ONCOLOGY (Vol. 22, pp. 14\u201314). GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS"},{"issue":"24","key":"10523_CR57","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1158\/1078-0432.CCR-11-1664","volume":"17","author":"SB Korets","year":"2011","unstructured":"Korets SB, Czok S, Blank SV, Curtin JP, Schneider RJ (2011) Targeting the mTOR\/4E-BP pathway in endometrial cancer. Clin Cancer Res 17(24):7518\u20137528","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10523_CR58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12964-024-01792-7","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Li Y, Hou X, Li J, Ma X (2024) Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications. Cell Communication Signal 22(1):436","journal-title":"Cell Communication Signal"},{"key":"10523_CR59","doi-asserted-by":"crossref","unstructured":"Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G.,\u2026 Cenciarelli,C. (2021). p53 signaling in cancer progression and therapy. Cancer cell international, 21(1), 703.","DOI":"10.1186\/s12935-021-02396-8"},{"issue":"8","key":"10523_CR60","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1007\/s11033-023-08580-5","volume":"50","author":"B Sun","year":"2023","unstructured":"Sun B, Zhao N, Cheng Y, Wang J (2023) A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer. Mol Biol Rep 50(8):6901\u20136912","journal-title":"Mol Biol Rep"},{"issue":"17","key":"10523_CR61","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1111\/jcmm.16574","volume":"25","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhang H, Li D, Zhou X, Qin Q, Zhang Q (2021) Caspase-3\u2010mediated GSDME induced pyroptosis in breast cancer cells through the ROS\/JNK signalling pathway. J Cell Mol Med 25(17):8159\u20138168","journal-title":"J Cell Mol Med"},{"key":"10523_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6169-0","volume":"20","author":"Y Yang","year":"2020","unstructured":"Yang Y, Liu PY, Bao W, Chen SJ, Wu FS, Zhu PY (2020) Hydrogen inhibits endometrial cancer growth via a ROS\/NLRP3\/caspase-1\/GSDMD-mediated pyroptotic pathway. BMC Cancer 20:1\u201319","journal-title":"BMC Cancer"},{"key":"10523_CR63","doi-asserted-by":"crossref","unstructured":"Teng, J. F., Mei, Q. B., Zhou, X. G., Tang, Y., Xiong, R., Qiu, W. Q.,\u2026 Wu, A. G.(2020). Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS\/NF-\u03baB\/NLRP3\/GSDMD signal axis in non-small cell lung cancer. Cancers, 12(1), 193.","DOI":"10.3390\/cancers12010193"},{"key":"10523_CR64","doi-asserted-by":"crossref","unstructured":"Di\u00e9guez-Mart\u00ednez, N., Espinosa-Gil, S., Yoldi, G., Meg\u00edas-Roda, E., Bolinaga-Ayala,I., Vi\u00f1as-Casas, M.,\u2026 Lizcano, J. M. (2022). The ERK5\/NF-\u03baB signaling pathway targets endometrial cancer proliferation and survival. Cellular and Molecular Life Sciences, 79(10), 524.","DOI":"10.1007\/s00018-022-04541-6"},{"key":"10523_CR65","doi-asserted-by":"crossref","unstructured":"Mizumoto, Y., Kyo, S., Kiyono, T., Takakura, M., Nakamura, M., Maida, Y.,\u2026 Inoue,M. (2011). Activation of NF-\u03baB is a novel target of KRAS-induced endometrial carcinogenesis. Clinical Cancer Research, 17(6), 1341\u20131350.","DOI":"10.1158\/1078-0432.CCR-10-2291"},{"issue":"8Supplement","key":"10523_CR66","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1158\/1538-7445.AM2013-2007","volume":"73","author":"AM Noonan","year":"2013","unstructured":"Noonan AM, Casablanca Y, Maxwell GL, Annunziata CM (2013) The NF-kB pathway is constitutively active in endometrial cancer. Cancer Res 73(8Supplement):2007\u20132007","journal-title":"Cancer Res"},{"issue":"1","key":"10523_CR67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11033-024-09447-z","volume":"51","author":"S Deng","year":"2024","unstructured":"Deng S, Yuan P, Sun J (2024) The role of NF-\u03baB in carcinogenesis of cervical cancer: opportunities and challenges. Mol Biol Rep 51(1):538","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10523_CR68","first-page":"311","volume":"68","author":"AL Zygulska","year":"2017","unstructured":"Zygulska AL, Krzemieniecki K, Pierzchalski P (2017) Hippo pathway-brief overview of its relevance in cancer. J Physiol Pharmacol 68(3):311\u2013335","journal-title":"J Physiol Pharmacol"},{"key":"10523_CR69","doi-asserted-by":"crossref","first-page":"1273345","DOI":"10.3389\/fonc.2023.1273345","volume":"13","author":"X Shen","year":"2023","unstructured":"Shen X, Li Q, Sun Y, Chen L, Xue F, Tian W, Wang Y (2023) The Hippo pathway in endometrial cancer: a potential therapeutic target? Front Oncol 13:1273345","journal-title":"Front Oncol"},{"key":"10523_CR70","first-page":"1","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Song T, Zhou S, Kong X (2019) YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11. Mol Med 25:1\u20139","journal-title":"Mol Med"},{"issue":"1","key":"10523_CR71","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12935-021-01999-5","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Wan R, Li Q, Rao Z, Wang Y, Zhang L, Teichmann AT (2021) Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer. Cancer Cell Int 21(1):306","journal-title":"Cancer Cell Int"},{"key":"10523_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","volume":"14","author":"BG Kim","year":"2021","unstructured":"Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol 14:1\u201320","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10523_CR73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X (2022) Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer 21(1):104","journal-title":"Mol Cancer"},{"issue":"2","key":"10523_CR74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7150\/ijbs.23230","volume":"14","author":"M Zhao","year":"2018","unstructured":"Zhao M, Mishra L, Deng CX (2018) The role of TGF-\u03b2\/SMAD4 signaling in cancer. Int J Biol Sci 14(2):111","journal-title":"Int J Biol Sci"},{"key":"10523_CR75","doi-asserted-by":"crossref","unstructured":"Snijesh, V. P., Krishnamurthy, S., Bhardwaj, V., Punya, K. M., Niranjana Murthy, A.S., Almutadares, M.,\u2026 Albaqami, W. F. (2024). SHH Signaling as a Key Player in Endometrial Cancer: Unveiling the Correlation with Good Prognosis, Low Proliferation, and Anti-Tumor Immune Milieu. International Journal of Molecular Sciences, 25(19), 10443.","DOI":"10.3390\/ijms251910443"},{"key":"10523_CR76","doi-asserted-by":"crossref","unstructured":"He, Y., Wang, J., Jiang, X., Gao, J., Cheng, Y., Liang, T.,\u2026 Zhang, G. (2022). Effects of an inhibitor of the SHH signaling pathway on endometrial cells of patients with endometriosis. BMC Molecular and Cell Biology, 23(1), 37.","DOI":"10.1186\/s12860-022-00426-5"},{"key":"10523_CR77","doi-asserted-by":"crossref","unstructured":"Bejar, J. F. G., Galende, E. Y., Zeng, Q., Genestie, C., Rouleau, E., de Bruyn, M.,\u2026 Leary, A. (2024). Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. Journal for Immunotherapy of Cancer, 12(7).","DOI":"10.1136\/jitc-2024-009143"},{"key":"10523_CR78","doi-asserted-by":"crossref","unstructured":"Chase DM, Kobayashi M, Gomez P, Lubinga SJ (2023) 1424 Treatment patterns and outcomes by mismatch repair\/microsatellite instability (MMR\/MSI) status among patients with primary advanced or recurrent endometrial cancer (pA\/rEC) in the united States","DOI":"10.1136\/jitc-2023-SITC2023.1424"},{"key":"10523_CR79","doi-asserted-by":"crossref","unstructured":"Whangbo J, Lee YS, Kim YJ, Kim J, Kim KG (2024) Predicting mismatch repair deficiency status in endometrial Cancer through Multi-Resolution ensemble learning in digital pathology. J Imaging Inf Med, 1\u20139","DOI":"10.1007\/s10278-024-00997-z"},{"issue":"1","key":"10523_CR80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-020-0199-6","volume":"5","author":"Q Wang","year":"2020","unstructured":"Wang Q, Peng H, Qi X, Wu M, Zhao X (2020) Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence. Signal Transduct Target Therapy 5(1):137","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"10523_CR81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X (2019) AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 18(1):153","journal-title":"Mol Cancer"},{"key":"10523_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0792-2","volume":"17","author":"WR Montor","year":"2018","unstructured":"Montor WR, Salas AROSE, Melo FHMD (2018) Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol Cancer 17:1\u201318","journal-title":"Mol Cancer"},{"key":"10523_CR83","doi-asserted-by":"crossref","unstructured":"Liu, X., Wang, W., Zhang, X., Liang, J., Feng, D., Li, Y.,\u2026 Ling, B. (2024). Metabolism pathway-based subtyping in endometrial cancer: An integrated study by multi-omics analysis and machine learning algorithms. Molecular Therapy-Nucleic Acids, 35(2).).","DOI":"10.1016\/j.omtn.2024.102155"},{"issue":"5","key":"10523_CR84","first-page":"167120","volume":"1870","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, Sharma G, Karmakar S, Banerjee S (2024) Multi-OMICS approaches in cancer biology: new era in cancer therapy. Biochim Et Biophys Acta (BBA)-Molecular Basis Disease 1870(5):167120","journal-title":"Biochim Et Biophys Acta (BBA)-Molecular Basis Disease"},{"issue":"8","key":"10523_CR85","first-page":"1687","volume":"108","author":"SA Byron","year":"2013","unstructured":"Byron SA, Gartside MG, Powell MA, Mutch DG, Goodfellow PJ, Pollock PM (2013) FGFR2 mutations are rare in endometrial cancer but have recurrence patterns in mixed endometrioid\/serous carcinomas. Br J Cancer 108(8):1687\u20131691","journal-title":"Br J Cancer"},{"issue":"2","key":"10523_CR86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrclinonc.2013.243","volume":"11","author":"R Murali","year":"2014","unstructured":"Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: are molecular features more important than morphology? Nat Reviews Clin Oncol 11(2):73\u201382","journal-title":"Nat Reviews Clin Oncol"},{"key":"10523_CR87","unstructured":"McConechy, M. K., Anglesio, M. S., Kalloger, S. E., Yang, W., Senz, J., Chow, C.,\u2026 Gilks, C. B. (2014). Subtypes of endometrial cancer and their relevance for pathogenesis and survival. Endocrine-Related Cancer 21(2):207\u2013221."},{"key":"10523_CR88","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1038\/srep08029","volume":"5","author":"Y Liang","year":"2015","unstructured":"Liang Y, Liu C, Lu C, Zhang W (2015) The prognostic significance of PTEN deletion in colorectal cancer. Sci Rep 5:8029","journal-title":"Sci Rep"},{"issue":"7447","key":"10523_CR89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67\u201373","journal-title":"Nature"},{"issue":"1","key":"10523_CR90","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12935-022-02736-2","volume":"22","author":"O Emam","year":"2022","unstructured":"Emam O, Wasfey EF, Hamdy NM (2022) Notch-associated LncRNAs profiling circuiting epigenetic modification in colorectal cancer. Cancer Cell Int 22(1):316","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10523_CR91","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1541-7786.MCR-15-0456","volume":"14","author":"T Xu","year":"2016","unstructured":"Xu T, Wang S, Ren C (2016) Role of miR-34a and FBXW7 mutations in cancer. Mol Cancer Res 14(3):267\u2013275","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10523_CR92","first-page":"147","volume":"24","author":"S Indumati","year":"2023","unstructured":"Indumati S, Apurva B, Gaurav G, Nehakumari S, Nishant V (2023) The role of MicroRNAs in the development of endometrial cancer: A literature review. J Reprod Infertility 24(3):147\u2013158","journal-title":"J Reprod Infertility"},{"issue":"23","key":"10523_CR93","first-page":"9826","volume":"65","author":"K Oda","year":"2005","unstructured":"Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of KRAS mutations in endometrial carcinomas with microsatellite instability. Cancer Res 65(23):9826\u20139828","journal-title":"Cancer Res"},{"key":"10523_CR94","doi-asserted-by":"crossref","unstructured":"Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., Shen, H.,\u2026 Cancer Genome Atlas Research Network. (2013). Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):7\u201373.","DOI":"10.1038\/nature12113"},{"key":"10523_CR95","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/1471-2407-14-487","volume":"14","author":"IL Tangen","year":"2014","unstructured":"Tangen IL, Krakstad C, Halle MK et al (2014) FOXA1 mutations in endometrial cancer: A potential prognostic biomarker. BMC Cancer 14:487","journal-title":"BMC Cancer"},{"key":"10523_CR96","unstructured":"Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Plotz, B. A.,\u2026Smit, V. T. (2016). Refinement of high-risk endometrial cancer classification using DNA methylation analysis. Clinical Cancer Research 22(1):240\u2013250."},{"issue":"3","key":"10523_CR97","first-page":"153","volume":"4","author":"MR Pal","year":"2012","unstructured":"Pal MR, Kamal A, Chakraborty P (2012) SFRP1 methylation as a biomarker in the progression of colon and endometrial cancers. Clin Epigenetics 4(3):153\u2013165","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10523_CR98","first-page":"789","volume":"9","author":"J Kim","year":"2016","unstructured":"Kim J, Zhang H, Goss AM (2016) SFRP1 hypermethylation is a predictor of favorable prognosis in certain endometrial cancers. Cancer Prev Res 9(10):789\u2013796","journal-title":"Cancer Prev Res"},{"issue":"2","key":"10523_CR99","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2014.59.7302","volume":"34","author":"GF Fleming","year":"2016","unstructured":"Fleming GF, Cibula D (2016) HER2 testing and clinical decisions in gynecologic cancers. J Clin Oncol 34(2):110\u2013120","journal-title":"J Clin Oncol"},{"issue":"9","key":"10523_CR100","first-page":"1165","volume":"17","author":"BD Smith","year":"2017","unstructured":"Smith BD, Shaw AT (2017) Trastuzumab in HER2-positive breast cancer treatment: A decade of success. Oncologist 17(9):1165\u20131176","journal-title":"Oncologist"},{"issue":"11","key":"10523_CR101","first-page":"R231","volume":"27","author":"NJ Chew","year":"2020","unstructured":"Chew NJ, Lunardi A (2020) FGFR and other receptor tyrosine kinase pathways in prostate cancer. Endocrine-related Cancer 27(11):R231\u2013R249","journal-title":"Endocrine-related Cancer"},{"issue":"2","key":"10523_CR102","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/jgh.12831","volume":"30","author":"Y Xiong","year":"2015","unstructured":"Xiong Y, Shi C, Han W, Peng X, Wang L, Yu Y, Li X (2015) RUNX3 hypermethylation in colorectal cancer and its potential for therapeutic targeting. J Gastroenterol Hepatol 30(2):252\u2013258","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10523_CR103","first-page":"23","volume":"7","author":"M Suzuki","year":"2019","unstructured":"Suzuki M, Yoshino M, Inoue H (2019) Role of DNA methylation in the pathogenesis of endometrial cancer. Med Sci 7(2):23","journal-title":"Med Sci"},{"issue":"1","key":"10523_CR104","first-page":"26","volume":"4","author":"H Tashiro","year":"2015","unstructured":"Tashiro H, Mikami T, Ohmichi M (2015) TGF-\u03b2 signaling and SMAD4 loss in endometrial cancer progression. J Clin Med 4(1):26\u201336","journal-title":"J Clin Med"},{"issue":"4","key":"10523_CR105","first-page":"4793","volume":"15","author":"H Peng","year":"2018","unstructured":"Peng H, Xie G, Liu W, Zhao X (2018) TGF-\u03b2 signaling pathway-related microRNA-181a expression in colorectal cancer and its association with prognosis. Oncol Lett 15(4):4793\u20134801","journal-title":"Oncol Lett"},{"issue":"8","key":"10523_CR106","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/15384047.2017.1345390","volume":"18","author":"Y Wei","year":"2017","unstructured":"Wei Y, Niu B, Wang L, Tan Y, Liu L (2017) Hippo pathway regulation and its function in cancer. Cancer Biol Ther 18(8):596\u2013603","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10523_CR107","first-page":"138","volume":"33","author":"Y Feng","year":"2014","unstructured":"Feng Y, Liang J, Wang Z, Zhang Z, Wei M, Wang L (2014) The role of miR-130a in the progression of hepatocellular carcinoma. Cell Physiol Biochem 33(1):138\u2013148","journal-title":"Cell Physiol Biochem"},{"key":"10523_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-3022-6","volume":"17","author":"M Suzuki","year":"2017","unstructured":"Suzuki M, Shigematsu Y, Naito M, Arakawa A (2017) DKK1 methylation as a potential biomarker for Wnt signaling activity in hepatocellular carcinoma. BMC Cancer 17:1\u201310","journal-title":"BMC Cancer"},{"key":"10523_CR109","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fimmu.2020.00186","volume":"11","author":"C Wei","year":"2020","unstructured":"Wei C, Qin M, Cao C, Wang Y, Xu X (2020) NLRP3 inflammasome activation and its role in tumor progression. Front Immunol 11:186","journal-title":"Front Immunol"},{"key":"10523_CR110","unstructured":"Eskander R (2023) NRG-GY018 Trial to Rule Benefit of IO\/Chemo in Advanced Endometrial Cancer. Cancer Network, NA-NA"},{"key":"10523_CR111","doi-asserted-by":"crossref","unstructured":"Disis, M. L., Adams, S. F., Bajpai, J., Butler, M. O., Curiel, T., Dodt, S. A.,\u2026Odunsi, K. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. Journal for immunotherapy of cancer 11(6):e006624.","DOI":"10.1136\/jitc-2022-006624"},{"key":"10523_CR112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-011-9291-2","volume":"30","author":"E Raymond","year":"2011","unstructured":"Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, Garc\u00eda-Carbonero R, Carrato A (2011) Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 30:19\u201326","journal-title":"Cancer Metastasis Rev"},{"key":"10523_CR113","doi-asserted-by":"crossref","unstructured":"Megino-Luque, C., Moiola, C. P., Molins-Escuder, C., L\u00f3pez-Gil, C., Gil-Moreno, A.,Matias-Guiu, X.,\u2026 Eritja, N. (2020). Small-molecule inhibitors (SMIs) as an effective therapeutic strategy for endometrial cancer. Cancers 12(10):2751.","DOI":"10.3390\/cancers12102751"},{"key":"10523_CR114","doi-asserted-by":"crossref","unstructured":"Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O.,\u2026 Santin,A. D. (2020). Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clinical Cancer Research 26(15):3928\u20133935.","DOI":"10.1158\/1078-0432.CCR-20-0953"},{"issue":"23","key":"10523_CR115","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.3390\/cancers16233918","volume":"16","author":"M Albert\u00ed-Valls","year":"2024","unstructured":"Albert\u00ed-Valls M, Olave S, Olom\u00ed A, Maci\u00e0 A, Eritja N (2024) Advances in immunotherapy for endometrial cancer: insights into MMR status and tumor microenvironment. Cancers 16(23):3918","journal-title":"Cancers"},{"key":"10523_CR116","doi-asserted-by":"crossref","unstructured":"Kumari, L., Mishra, L., Sharma, Y., Chahar, K., Kumar, M., Patel, P.,\u2026 Kurmi, B.D. (2024). NOTCH Signaling Pathway: Occurrence, Mechanism, and NOTCH-Directed Therapy for the Management of Cancer. Cancer Biotherapy & Radiopharmaceuticals 39(1):19\u201334.","DOI":"10.1089\/cbr.2023.0023"},{"issue":"7","key":"10523_CR117","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/ph17070949","volume":"17","author":"A de Pellegars-Malhortie","year":"2024","unstructured":"de Pellegars-Malhortie A, Lasorsa P, Mazard L, Granier T, F., Pr\u00e9vostel C (2024) Why is Wnt\/\u03b2-Catenin not yet targeted in routine Cancer care?? Pharmaceuticals 17(7):949","journal-title":"Pharmaceuticals"},{"key":"10523_CR118","doi-asserted-by":"crossref","unstructured":"Zhang, X., Huang, P., Wang, L., Chen, S., Basappa, B., Zhu, T.,\u2026 Pandey, V. (2022).Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma. Cell death & disease 13(6):558.","DOI":"10.1038\/s41419-022-04982-8"},{"key":"10523_CR119","doi-asserted-by":"crossref","unstructured":"Bhardwaj, V., Sharma, A., Parambath, S. V., Gul, I., Zhang, X., Lobie, P. E.,\u2026 Pandey,V. (2022). Machine learning for endometrial cancer prediction and prognostication. Frontiers in oncology 12:852746.","DOI":"10.3389\/fonc.2022.852746"},{"issue":"9","key":"10523_CR120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/ijgc-2023-004622","volume":"33","author":"S Piedimonte","year":"2023","unstructured":"Piedimonte S, Rosa G, Gerstl B, Sopocado M, Coronel A, Lleno S, Vicus D (2023) Evaluating the use of machine learning in endometrial cancer: A systematic review. Int J Gynecol Cancer 33(9):1383\u20131393","journal-title":"Int J Gynecol Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10523-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:35:23Z","timestamp":1766853323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10523-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10523"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10523-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}